GMED

Expansion of Distribution Rights: Henry Schein, Inc. has secured exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus product, effective January 1, 2026, which is expected to enhance its Dental business and support stock momentum.

Market Growth and Health Impact: The global dental caries treatment market is projected to grow significantly, driven by the rising prevalence of dental diseases and the introduction of innovative treatment options like Curodont, which addresses early-stage cavities without traditional drilling.

Strategic Partnerships: The company has also formed a strategic partnership with Oral Genome to distribute advanced salivary testing nationwide, further expanding its service offerings in the dental sector.

Stock Performance and Rankings: Henry Schein's shares have seen a slight increase, and the company holds a Zacks Rank #3 (Hold), while other medical stocks like Globus Medical and Boston Scientific are performing better in the market.

AI Integration in Dental Software: Henry Schein One has introduced AI and automation workflows, including Voice Notes, at the 2025 Greater New York Dental Meeting, enhancing practice efficiency and revenue management through better claims processing and patient communication.

Partnership with AWS: The company has partnered with Amazon Web Services to integrate generative AI technologies across its platforms, aiming to improve the overall dental experience from patient intake to treatment planning.

Market Performance and Growth: Despite a recent 1.2% drop in shares, Henry Schein's stock has seen a 15.4% increase over the past month, with projected earnings growth of 3.6% for 2025, supported by strong sales and operational improvements.

Innovative Features for Practices: New features like the Forms workflow and Detect AI enhance patient data accuracy and diagnostic confidence, while multilingual support and real-time transcription reduce administrative burdens, allowing dental teams to focus more on patient care.